Member Info for Chris0123

Once again, VS refrained from naming the Medical Centre but it is "prestigious", a word he used again and stated they are going through "very difficult and detailed budget negotiations" . I think the onboarding of a top Medical Centre will probably not dramatically shift share purchases but likewise, it won't cause a sell off. The kudos of having a top ranked US facility helping Hemogenyx is more likely to gain traction within population of industry specialists. Great partnerships count a lot in this game. Let's hope the financial agreement between them gives the new MC enough incentive to deliver end points quickly. GLA

Haywain - hope you are right about Dana Faber - ranked in 2023-2024 No.2 in treatment of Pedriatric Cancer with Sloan Kettering 14th. Penn only ranked 47th in pediatric cancer, this might suggest an approach by someone or a referral by Penn.

Despite patient numbers being low I think we all agree if it works in a couple of patients, as well as Godsend to the parents, funders will take note I am sure. GLA

Thanks dhub. Yes, VS perhaps communicating as much as he is able at this time re the Medical Centre. Who knows, between now and AGM there may be more news. GL you and all.

To be fair about the content of the RNS there are new things in there. 1). They have added a prestigious US Medical Centre to expedite the clinical trial timeline. 2). Internal review boards of BOTH clinical sites taking place (so progress it seems at 2nd site too). 3). Pediatric inclusion and to amend the clinical protocol to enable pediatric use, which Hemo believes it can also effectively treat. 4). They have been specific about the tumor cancer possibilities with CBR - namely epithelial ovarian carcinoma (so CBR not grounded to a halt in Govt labs as supposed by many) & Hemo themselves progressing rigorous testing for IND studies - 9 out of 10 ovarian cancers are "epithelial"

My take on the above:

1. Gut feeling is that "prestigious" US Medical Centre has not been named as this may be linked to funding by them and perhaps with conditional requirements by them to extend to pediatric trials. VS states they "have added" the new Centre, he has not said they are in discussions with. So, in my view, the name of the 2nd Medical Centre has been withheld for no other reason except that it will be a funding relationship and likely pediatric related.

2. CBR - they have drilled this down to a possible set of constructs that will enable them to test on ovarian cancer and this will enable them to move in house toward possible funding for that specific condition. Whilst the virus solutions are being worked on Hemo know that they have to monetize CBR driven cures themselves in the meantime and have isolated ovarian cancer with which to achieve that.

Purely my summation and reading into what has been communicated. You have to admire the Hemo team. Strapped for cash long term yet still exploring new avenues and a new partnership to get things moved through the pipeline. Perhaps this shows the agility of the company as I think VS once referred to. Things are clearly not dead in the water, because cash is low and as some might like others to believe. He has not laid anyone off to preserve cash, he is holding on to his key scientist assets and is putting them to work on the science. Get that right and non-dilutive funding will follow. No one of any note has left the company because it is in need to future cash- why? - because they too believe in the science and refreshingly, the boss believes in them. Reasons to be cheerful today! All in my opinion GLA

Just had a notion to look up the meaning of the name "Vladislav" and what popped up was "one who owns glory" - Diary note: remind the CEO. Happy days!!

Thanks for the link to the Dengue article HT. Dengue also covered on national news last night. When it becomes a problem in the northern hemisphere people begin to take note. The solution to which is in Hemo and CBR hands. If you have a solution to a problem money should follow hundreds of millions affected each year. An opportunity for Hemo to put their work on this into sharper focus out there, 0a chance to be ahead of the curve. GLA

Less than 1 million shares traded in nearly 4 hours - no need to stress in my view. There's no mad rush for the door or am I missing something?

GLA

Magnificent News just in:

"Symons tries to hoodwink seasoned shareholders and news falls on deaf ears!" - unless you can reveal who your "deepthroat" is of course.

GL you and all!

Jeeper's Charles, you've been busy - but thank you. Time on your hands unlike me. Hopefully you'll not be setting us project work for completion over the weekend. GL to you and all!

One gets a sense this morning that we are very slowly crawling out of the doldrums. Maybe Mr S has been seen backslapping a big pharma guy at BIO 24. We live in hope. GLA (PS -Try to be a bit more upbeat some of you, the share can quite easily drop on it's own without Posters on here sticking the boot in!)

I think dhub is correct regarding JHFH he is still around and topped up and is still holding. To be fair we are all trying to guess outcomes and timelines and it is extremely difficult to get right. This BB is about sharing those thoughts and ideas about how and when things might happen. You will sell or buy at your own peril or good fortune. I suspect that if this company share soars in a sustained manner there will be many more thanking JHFH for his early input. If timing was easy we would all be rich. Like some CEO's there are quiet spells and holding investors taking timeout does no harm in the grand scheme of things. GLA

Yes, the mouse is still going strong. He later went on to work in the movie business, he played Mr Jingles in The Green Mile. He was turned down for Ratatoiulle for obvious reasons. GLA

The trials have started VS stated it just depends how you define a trial. There are a significant amount of steps pre first injection so some realism needed I imagine. As frustrating as radio silence is, if you are sticking around as an investor, try to stay calm. GLA

Ah yes the "breakthrough news". A little disappointed that VS has been distracted by work on a constipation drug if that's the breakthrough he's referring to. However I think they are laser focused on trials and the Penn video kindly shared illustrates that dramatic and positive results in just one patient can take this share out of the doldrums. GLA

The Grim Reaper is back, avert thine eyes lest he take your soul and separate you from your shares in Hemogenyx. I have figured out the meaning of "Ssccss" - it is not a name derivative, it's a sound. The sound of the Grim Reaper's scythe as it glides through the harvest and cuts down the abundance of belief in this company. Is that dramatic enough for you GR? GL all.

You can only make a judgement for you Woodcot. In sharing your sale, at least you have allowed us to know the motivation behind it... nothing sinister can be drawn from it. All the best.

I guess there have been plenty of confirmed buys by posters on here which have appeared as sells in the past. Not one to get too hung up on. Hopefully we get some big buys this week to grab all our attention. GLA

Cyrox have you forgotten about all the years of research and development which will put odds in favour of CT success. Its not as binary as you suggest. You have more reason to be confident than not.

MrI I think he quickly tagged :hoped" to "more than one" and you would expect this with Prevail Infoworks' expertise. Have novdoubt we are I Phase 1 the preparation pre injection is vitally important so work very much front loaded. The injection and monitoring is a sit and wait situation and if the preparation and science is good we should get some success. On the money situation Prevail are vested in the business and are probably holding back on further support but I cannot see them

holding back if absolutely needed. It would be like standing by and doing nothing to save the sinking ship you are relying on to get to shore and the land of plenty or CBR. We are going to be okay. GLA

The company featured in this link like to invest in disruptive biotech CBR seems a perfect fit. Worth a call perhaps VS.

https://www.labiotech.eu/podcast/biotech-investment-landscape-2024/